Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
EBS
↓ PDF (Pro)Emergent BioSolutions Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNYSE
$9.19
+1.49%today
MKT CAP
$474M
+6.4% · 1Y
Earnings History
+132.7%
+984.2%
-490.9%
+184.0%
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Analyst Targets
Current price
$9.19
Low
$12.00
Analyst Mean
$12.00
High
$12.00
2 analystsStrong Buy
Full Financials
Trailing P/E-
Forward P/E3.1x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+5.0%
5y Revenue CAGR-12.8%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership3.1%
Institutional Ownership82.0%
Short % of Float18.91%
Days to Cover12.2d
1 Week+12.5%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| DEGOLYER DONALD W | Director | Sale | 15,481 | $8.36 | $0.13M | 2026-05-01 |
| ZOON KATHRYN C. | Director | Sale | 17,202 | $8.36 | $0.14M | 2026-05-01 |
| DAYAL SUJATA TYAGI | Director | Sale | 13,761 | $8.36 | $0.12M | 2026-05-01 |
| RICHARD RONALD B | Director | Stock | 25,344 | $0.00 | $0.00M | 2026-04-30 |
| HARSANYI ZSOLT | Chairman of the Board | Stock | 25,344 | $0.00 | $0.00M | 2026-04-30 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Blackrock Inc. | institution | 8.24% | $0.04B | -0.20% | 2025-12-31 |
| Oak Hill Advisors, L.P. | institution | 7.00% | $0.03B | +0.00% | 2025-12-31 |
| Vanguard Group Inc | institution | 6.88% | $0.03B | +0.38% | 2025-12-31 |
| State Street Corporation | institution | 5.22% | $0.02B | +10.25% | 2025-12-31 |
| American Century Companies Inc | institution | 4.72% | $0.02B | +2.40% | 2025-12-31 |
| Dimensional Fund Advisors LP | institution | 4.36% | $0.02B | +5.25% | 2025-12-31 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | fund | 3.95% | $0.02B | +1.45% | 2026-03-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | fund | 3.19% | $0.02B | +11.16% | 2026-03-31 |
| Charles Schwab Investment Management, Inc. | institution | 3.13% | $0.01B | +17.16% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 3.11% | $0.01B | -0.30% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 2.46% | $0.01B | -1.73% | 2026-03-31 |
| Palisade Capital Management, L.P. | institution | 2.45% | $0.01B | -11.24% | 2025-12-31 |
| Geode Capital Management, LLC | institution | 2.42% | $0.01B | -2.24% | 2025-12-31 |
| Morgan Stanley | institution | 2.24% | $0.01B | +118.90% | 2025-12-31 |
| SCHWAB STRATEGIC TRUST-Schwab Fundamental U.S. Small Company ETF | fund | 1.92% | $0.01B | +28.49% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 1.09% | $0.01B | -6.91% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.99% | $0.00B | +1.05% | 2026-02-28 |
| VANGUARD HORIZON FUNDS-Vanguard Strategic Equity Fund | fund | 0.90% | $0.00B | +0.00% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 Value ETF | fund | 0.86% | $0.00B | -2.87% | 2026-03-31 |
| iShares Trust-iShares Biotechnology ETF | fund | 0.73% | $0.00B | -0.46% | 2026-03-31 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| BIOA | $820M | - | - | - | - | -27.1% | 0% | 2.04 | 0.00% |
| ETON | $833M | 60 | - | 16.4 | - | - | - | - | 0.00% |
| PCRX | $937M | 58 | 193.0 | 7.0 | - | - | - | - | 0.00% |
| CRON | $990M | 5 | - | - | - | - | - | - | 0.00% |
| AMPH | $1.1B | 100 | 11.8 | 6.9 | - | - | - | - | 0.00% |
| XERS | $1.1B | 60 | 94.7 | 17.0 | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for EBS.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.